Vimta Labs (VIMTALABS)
Fast GrowerFairStock Score: 33/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹617 |
| Market Cap | ₹2,757.18 Cr |
| P/E Ratio | 34.6 |
| ROCE | 25.22% |
| ROE | 22.1% |
| Dividend Yield | 0.32% |
| Profit Growth | 11.37% |
| Debt/Equity | 0.01 |
| Sales Growth | 13.67% |
| Promoter Holding | 35.9% |
| 52-Week Range | ₹376.05 — ₹735 |
| Sector | Healthcare Services |
| Book Value | ₹102.28 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Vimta Labs strikes me as a good, not great, business that is currently priced as if it were a great one. The financial health is excellent: debt/equity of 0.02, ROE at 22.10%, ROCE at 25.22%, and a Piotroski F-Score of 7/9. That tells me the company generates solid returns without leverage, and its operating fundamentals have been sound. It appears to have some moat in healthcare research, analytics and technology, though the numbers alone don't quantify the durability of that moat. Promoter holding of 35.90% is adequate but not commanding.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer